The authors focused on the current surgical treatment of resectable gastric cancer, and
significance of peri-and post-operative chemo or chemoradiation. Gastric cancer is the 4 th …

Context Despite potentially curative resection of stomach cancer, 50% to 90% of patients die
of disease relapse. Numerous randomized clinical trials (RCTs) have compared surgery …

Purpose The first planned interim analysis (median follow-up, 3 years) of the Adjuvant
Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine …

Purpose Surgical resection of gastric cancer has produced suboptimal survival despite
multiple randomized trials that used postoperative chemotherapy or more aggressive …

Background Historical data and recent studies show that standardised extended (D2)
lymphadenectomy leads to better results than standardised limited (D1) lymphadenectomy …

Purpose The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the
first study to our knowledge to investigate the role of postoperative chemoradiotherapy …

Background A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves
survival among patients with incurable locally advanced or metastatic gastric …

Background Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We
tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer …

Gastric cancer is the second most frequent cause of cancer death worldwide, although much
geographical variation in incidence exists. Prevention and personalised treatment are …

Objective: This update reviews the epidemiology and surgical management, and the
controversies of gastric adenocarcinoma. We provide the relevance of outcome data to …